BioCorp and Diabeloop announced today that they are entering a cooperation agreement to develop new personalized diabetes treatments.
Diabeloop develops automated insulin delivery (AID) systems, including a self-learning algorithm hosted in a handset and connected to a continuous glucose monitoring (CGM) system and an insulin pump. The platform analyzes glucose data, calculates the right dose of insulin for administration and automatically administers it.
BioCorp develops Mallya, an intelligent sensor for insulin injection pens that has CE mark approval in Europe. The platform is compatible with any disposable insulin pen and enables reliable monitoring for doses selected for injection and it offers patients with diabetes better compliance with their treatment.
The collaboration between the two companies is set to integrate Mallya into Diabeloop’s technological environment, according to a news release.
Through the partnership between the companies, patients who use insulin pens are slated to benefit from a new, easy-to-use and personalized solution to improve their quality of care and life on a daily basis.
“We are very pleased to combine our R&D capabilities with the common ambition to improve the quality of care for patients with diabetes,” BioCorp CEO Eric Dessertenne said in the release. “The technological platform developed by Diabeloop in the field of insulin pumps, which reproduces the functioning of the pancreas thanks to AI, has real potential in the insulin pen market. Insulin-dependent people, users of these pens, are indeed looking for digital services that are increasingly rich in information and advice for better compliance with their insulin intake.”
“We are delighted with this agreement with Biocorp, a partner with great expertise,” Diabeloop co-CEO Marc Julien added. “This cooperation opens up new opportunities to bring Diabeloop’s simple and personalized interoperable technology to people living with diabetes who use insulin pens to perform their multiple insulin injections every day.”
